Role of microRNAs in breast cancer development and their potential as biomarkers
https://doi.org/10.17650/1994-4098-2018-14-3-40-47
Abstract
Breast cancer is the 2nd most common malignant disease after lung cancer; about 1 in 8 women will develop breast cancer in her lifetime. Cancer progression is a serious complication of the disease that encourages comprehensive investigation of molecular mechanisms underlying breast cancer development. This is also important for healthcare professionals involved in patient management, since they have to choose an optimal treatment regimen. This article discusses the role of microRNAs in the development of breast cancer, their biogenesis, classification, association with various molecular subtypes of breast cancer, and their potential role in the development of new targeted drugs for breast cancer therapy. Current research on the role of microRNAs in breast cancer progression is focused on the development of markers for breast cancer prognosis, diagnostic markers and new targeted drugs.
About the Authors
K. A. Grishina
Research Center for Medical Genetics
Russian Federation
1 Moskvorechye St., Moscow 115522
Competing Interests: The authors declare no conflict of interest.
Russian Federation
1 Moskvorechye St., Moscow 115522
Competing Interests: The authors declare no conflict of interest.
V. A. Khaylenko
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests: The authors declare no conflict of interest.
Russian Federation
24 Kashirskoe Shosse; Moscow 115478
1 Ostrovityanova St., Moscow 117997
Competing Interests: The authors declare no conflict of interest.
D. V. Khaylenko
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests: The authors declare no conflict of interest.
Russian Federation
24 Kashirskoe Shosse; Moscow 115478
1 Ostrovityanova St., Moscow 117997
Competing Interests: The authors declare no conflict of interest.
A. V. Karpukhin
Research Center for Medical Genetics
Russian Federation
1 Moskvorechye St., Moscow 115522
Competing Interests: The authors declare no conflict of interest.
Russian Federation
1 Moskvorechye St., Moscow 115522
Competing Interests: The authors declare no conflict of interest.
References
1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30. PMID: 23335087. DOI: 10.3322/caac.21166.
2. Jemal A., Bray F., Center M.M. et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90. PMID: 21296855. DOI: 10.3322/caac.20107.
3. Sica A., Larghi P., Mancino A. et al. Macrophage polarization in tumour progression. Cancer Biol 2008;18(5):349–55. PMID: 18467122. DOI: 10.1016/j.semcancer.2008.03.004.
4. Scully O.J., Bay B.H., Yip G. et al. Breast cancer metastasis. Cancer Genomics Proteomics 2012;9(5):311–20. PMID: 22990110.
5. Bartels C.L., Tsongalis G.J. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009;55(4):623–31. PMID: 19246618. DOI: 10.1373/clinchem.2008.112805.
6. Esquela-Kerscher A., Slack F.J. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006;6(4):259–69. PMID: 16557279. DOI: 10.1038/nrc1840.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004;116(2):281–97. PMID: 14744438.
8. Christodoulatos G.S., Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: quo vadis? World J Clin Oncol 2014;5(2):71–81. PMID: 24829853. DOI: 10.5306/wjco.v5.i2.71.
9. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6(5):376–85. PMID: 15852042. DOI: 10.1038/nrm1644.
10. O’Hara S.P., Mott J.L., Splinter P.L. et al. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology 2009;136(1):17–25. PMID: 19049808. DOI: 10.1053/j.gastro.2008.11.028.
11. Croce C.M., Calin G.A. MiRNAs, cancer, and stem cell division. Cell 2005;122(1): 6–7. PMID: 16009126. DOI: 10.1016/j. cell.2005.06.036.
12. Tanzer A., Stadler P.F. Molecular evolution of a microRNA cluster. J Mol Biol 2004;339(2):327–35. PMID: 15136036. DOI: 10.1016/j.jmb.2004.03.065.
13. Calin G.A., Sevignani C., Dumitru C.D. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101(9):2999–3004. PMID: 14973191. DOI: 10.1073/pnas.0307323101.
14. Andorfer C.A., Necela B.M., Thompson E.A. et al. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 2011l;17(6):313–9. PMID: 21376668. DOI: 10.1016/j.molmed.2011.01.006.
15. McGuire A., Brown J.A., Kerin M.J. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitorin. Cancer Metastasis Rev 2015;34(1):145–55. PMID: 25721950. DOI: 10.1007/s10555-015-9551-7.
16. Wang W., Luo Y. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B 2015;16(1):18–31. PMID: 25559952. DOI: 10.1631/jzus.B1400184.
17. Kong W., He L., Coppola M. et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010;285(23):17869–79. PMID: 20371610. DOI: 10.1074/jbc. M110.101055.
18. Jiang S., Zhang H.W., Lu M.H. et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010;70(8):3119–27. PMID: 20354188. DOI: 10.1158/0008-5472.CAN-09-4250.
19. Ovcharenko D., Kelnar K., Johnson C. et al. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res 2007;67(22):10782–8. PMID: 18006822. DOI: 10.1158/0008-5472.CAN-07-1484.
20. Chiang C.H., Hou M.F., Hung W.C. Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta 2013;1830(4):3067–76. PMID: 23333633. DOI: 10.1016/j.bbagen.2013.01.009.
21. Lei R., Tang J., Zhuang X. et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene 2014;33(10):1287–96. PMID: 23474751. DOI: 10.1038/onc.2013.65.
22. Liu Y., Zhao J., Zhang P.Y. et al. MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med Sci Monit 2012;18(8):BR299–308. PMID: 22847191.
23. Tang W., Yu F., Yao H. et al. MiR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 2014;33(20):2629–38. PMID: 23752185. DOI: 10.1038/onc.2013.214.
24. Guttilla I.K., White B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009;284(35):23204–16. PMID: 19574223. DOI: 10.1074/jbc. M109.031427.
25. Ma L., Young J., Prabhala H. et al. MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12(3):247–56. PMID: 20173740. DOI: 10.1038/ncb2024.
26. Johnson S.M., Lin S.Y., Slack F.J. The time of appearance of the C. elegans let-7 microRNA is transcriptionally controlled utilizing a temporal regulatory element in its promoter. Dev Biol 2003;259(2):364–79. PMID: 12871707.
27. Yu F., Yao H., Zhu P. et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131(6):1109–23. PMID: 18083101. DOI: 10.1016/j.cell.2007.10.054.
28. Hu X., Guo J., Zheng L. et al. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res 2013;11(3):240–50. PMID: 23339187. DOI: 10.1158/1541-7786.MCR-12-0432.
29. Rubin R., Arzumanyan A., Soliera A.R. et al. Insulin receptor substrate (IRS)-1 regulates murine embryonic stem (mES) cells self-renewal. J Cell Physiol 2007;213(2):445–53. PMID: 17620314. DOI: 10.1002/jcp.21185.
30. Spizzo R., Nicoloso M.S., Lupini L. et al. MiR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010;17(2):246–54. PMID: 19730444. DOI: 10.1038/cdd.2009.117.
31. Wang S., Bian C., Yang Z. et al. MiR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009;34(5):1461–6. PMID: 19360360.
32. Sachdeva M., Mo Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010;70(1):378–87. PMID: 19996288. DOI: 10.1158/0008-5472.CAN-09-2021.
33. Hu J., Guo H., Li H. et al. MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4. PLoS One 2012;7(9):e45965. PMID: 23049906. DOI: 10.1371/journal.pone.0045965.
34. Li X., Roslan S., Johnstone C.N. et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene 2014;33(31):4077–88. PMID: 24037528. DOI: 10.1038/onc.2013.370.
35. Dykxhoorn D.M., Wu Y., Xie H. et al. MiR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009;4(9):e7181. PMID: 19787069. DOI: 10.1371/journal.pone.0007181.
36. Gregory P.A., Bracken C.P., Bert A.G. et al. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008;7(20):3112–8. PMID: 18927505. DOI: 10.4161/cc.7.20.6851.
37. Iorio M.V., Casalini P., Piovan C. et al. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009;69(6):2195–200. PMID: 19276373. DOI: 10.1158/0008-5472.CAN-08-2920.
38. Chao C.H., Chang C.C., Wu M.J. et al. MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest 2014;124(7):3093–106. PMID: 24911147. DOI: 10.1172/JCI73351.
39. Png K.J., Yoshida M., Zhang X.H. et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 2011;25(3):226–31. PMID: 21289068. DOI: 10.1101/gad.1974211.
40. Tavazoie S.F., Alarcón C., Oskarsson T. et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451(7175):147–52. PMID: 18185580. DOI: 10.1038/nature06487.
41. Heyn H., Engelmann M., Schreek S. et al. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer 2011;129(12):2797–806. PMID: 21618216. DOI: 10.1002/ijc.25962.
42. Mukhtar R.A., Nseyo O., Campbell M.J. et al. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 2011;11(1):91–100. PMID: 21171924. DOI: 10.1586/erm.10.97.
43. Yang J., Zhang Z., Chen C. et al. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene 2014;33(23):3014–23. PMID: 23831570. DOI: 10.1038/onc.2013.258.
44. Gilad S., Meiri E., Yogev Y. et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008;3(9):e3148. PMID: 18773077. DOI: 10.1371/journal. pone.0003148.
45. Mitchell P.S., Parkin R.K., Kroh E.M. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105(30):10513–8. PMID: 18663219. DOI: 10.1073/pnas.0804549105.
46. Chen X., Gao C., Li H. et al. Identification and characterization of microRNAs in raw milk during different periods of lactation, commercial fluid, and powdered milk products. Cell Res 2010;20(10):1128–37. PMID: 20548333. DOI: 10.1038/cr.2010.80.
47. Blenkiron C., Goldstein L.D., Thorne N.P. et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007;8(10):R214. PMID: 17922911. DOI: 10.1186/gb-2007-8-10-r214.
48. Farazi T.A., Horlings H.M., Ten Hoeve J.J. et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 2011;71(13):4443–53. PMID: 21586611. DOI: 10.1158/0008-5472.CAN-11-0608.
49. Buffa F.M., Camps C., Winchester L. et al. MicroRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011;71(17):5635–45. PMID: 21737487. DOI: 10.1158/0008-5472.CAN-11-0489.
50. Taylor M.A., Sossey-Alaoui K., Thompson C.L. et al. TGF-β upregulates miR- 181a expression to promote breast cancer metastasis. J Clin Invest 2013;123(1): 150–63. PMID: 23241956. DOI: 10.1172/JCI64946.
51. Chen W.X., Hu Q., Qiu M.T. et al. MiR- 221/222: promising biomarkers for breast cancer. Tumour Biol 2013;34(3):1361–70. PMID: 23529451. DOI: 10.1007/s13277-013-0750-y.
52. Cuk K., Zucknick M., Heil J. et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013;132(7):1602–12. PMID: 22927033. DOI: 10.1002/ijc.27799.
53. Nguyen D.P., Li J., Yadav S.S. et al. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU Int 2014;114(2):168–76. PMID: 24215139. DOI: 10.1111/bju.12488.
54. Wang F., Zheng Z., Guo J. et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010;119(3):586–93. PMID: 20801493. DOI: 10.1016/j.ygyno.2010.07.021.
55. Mattie M.D., Benz C.C., Bowers J. et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24. PMID: 16784538. DOI: 10.1186/1476-4598-5-24.
56. Shi W., Gerster K., Alajez N.M. et al. MicroRNA301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011;71:2926. PMID: 21393507. DOI: 10.1158/0008-5472.CAN-10-3369.
57. Roth C., Rack B., Müller V. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010;12(6):R90. PMID: 21047409. DOI: 10.1186/bcr2766.
58. Si M.L., Zhu S., Wu H. et al. MiR-21-mediated tumor growth. Oncogene 2007;26(19):2799–803. PMID: 17072344. DOI: 10.1038/sj.onc.1210083.
59. Meng F., Henson R., Lang M. et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130(7):2113–29. PMID: 16762633. DOI: 10.1053/j.gastro.2006.02.057.
60. Weidhaas J.B., Babar I., Nallur S.M. et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007;67(23):11111–6. PMID: 18056433. DOI: 10.1158/0008-5472.CAN-07-2858.
61. Ma L., Reinhardt F., Pan E. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010;28(4):341–7. PMID: 20351690. DOI: 10.1038/nbt.1618.
62. Barh D., Malhotra R., Ravi B. et al. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 2010;17(1):70–80. PMID: 20179807.
Review
For citations:
Grishina K.A., Khaylenko V.A., Khaylenko D.V., Karpukhin A.V. Role of microRNAs in breast cancer development and their potential as biomarkers. Tumors of female reproductive system. 2018;14(3):40-47. (In Russ.) https://doi.org/10.17650/1994-4098-2018-14-3-40-47
Views:
613
Email this article 